Mounjaro®
Starting from £179.99/mo
Start journey Learn moreWegovy's UK private price has not fallen in 2025 or 2026. If anything, costs across the injectable weight-loss market have moved upward: Eli Lilly raised tirzepatide's list price significantly from 1 September 2025, and market prices for semaglutide have broadly followed suit. That context matters if you're deciding whether to wait or start now — and it's a question our prescribers hear most weeks. These are prescription-only medicines that require a clinical assessment before any treatment can be issued; the price you pay should always include that assessment, not sit underneath it as a hidden extra.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The honest answer is: nobody can say with confidence that the Wegovy price is going down in the near term. UK private pricing for injectable weight-loss medicines is set by manufacturers and then adjusted by each pharmacy or clinic to cover their own costs. When Novo Nordisk's supply constraints eased in late 2024 and into 2025, some hoped that would bring prices down. It hasn't, at least not materially. Demand remains high, the manufacturing and cold-chain logistics behind a weekly injection are genuinely expensive, and the costs of legitimate clinical oversight (identity checks, prescriber time, safe dispensing) don't disappear just because a medicine becomes more widely available.
On the Mounjaro side, the market shift was stark enough to be widely reported: Eli Lilly raised its UK list price for tirzepatide from around £122 per pen to as high as around £330 for the highest dose from September 2025. That raised the floor for injectable weight-loss medicines across the board. If you're wondering whether Wegovy will go down in price over the longer term, the answer depends on competition, NICE's NHS rollout pace, and manufacturing scale, factors no clinic can predict reliably. What's knowable now is what you'd actually pay, and what that should cover.
Typical private prices for Wegovy in the UK since late 2025 range roughly £149–£375 per month depending on dose and provider, based on widely reported market data. Those are the numbers to benchmark against, hedged, because they shift, and because dose affects them significantly. The monthly cost of Wegovy rises as treatment titrates upward, which is worth planning for from the start.
This is where the decision gets complicated. A low headline number looks appealing until you work out what's missing. Some providers charge separately for the initial consultation, the prescription itself, each follow-up review, and delivery. Others bundle some of these and not others. A few charge for the medicine only and leave clinical oversight as an optional extra, which, for a prescription-only medicine, it isn't optional at all under UK law.
It's worth asking, before committing to any provider, whether that price covers: a consultation with a qualified prescriber (not a questionnaire auto-assessed by software), a repeat clinical review before each new supply, and any aftercare if you have questions mid-treatment. You can verify that a provider operates a genuine pharmacy by checking the GPhC pharmacy register, any legitimate UK online pharmacy dispensing prescription medicines will be on it. That takes thirty seconds and removes a lot of doubt.
Delivery costs vary too. Some providers charge £5–£15 per order for tracked cold-chain shipping; others include it. For a medicine that needs refrigeration, the packaging and logistics matter, and cutting costs there isn't something you'd want a provider to do.
We're not the cheapest option. That's a deliberate choice, not an oversight. One transparent price at nume covers the consultation, the prescription, the medicine, and free next-working-day DPD delivery, tracked, temperature-appropriate, in plain packaging. There are no subscription commitments and no auto-renewals; every repeat goes back to a prescriber for clinical re-review before it's issued. You can see current treatment pricing on our weight-loss treatments page.
We don't print per-pen prices in our articles because pricing can shift, and locking a number into a page that stays live for months creates the wrong impression. Readers who want to understand how much a dose of Wegovy actually is will find a breakdown of what each pen in the titration schedule contains and costs. If you want to understand the full picture of Wegovy pricing in the UK, that page goes into more detail on what market rates look like at different doses and why the range is as wide as it is.
The clinical team at nume includes GPhC-registered Independent Prescribers who review every consultation personally on the day it arrives. That's the thing a lower-cost provider is most likely to have trimmed. It's also the thing that keeps treatment safe.
A small monthly saving on a prescription-only medicine is a poor trade-off if it comes at the cost of genuine clinical oversight, a verifiable supply chain, or accessible aftercare. Wegovy (semaglutide) is a Black Triangle medicine still under additional MHRA monitoring, as the NHS semaglutide page makes clear, and its side-effect profile (predominantly gastrointestinal, most noticeable at the start and after dose increases) means having a prescriber you can actually reach matters.
The MHRA has also warned publicly about counterfeit injectable weight-loss pens circulating online and through social media. Pens sold without a proper prescription and clinical assessment are a significant red flag regardless of price. Many patients also ask whether Wegovy went down in price after supply improved in 2024 and 2025, and the evidence suggests it largely did not, which makes choosing a provider on clinical quality rather than headline cost all the more important. Those aren't bureaucratic niceties, they're the conditions under which treatment is both legal and safe.
Some providers advertise lower figures and invite patients to read up on whether Wegovy will come down in price before committing, but if you want a clearer picture of whether the cost of Wegovy is actually going down, that question is worth exploring carefully before you decide, because watching for price drops is a poor substitute for verifying that a pharmacy is GPhC-registered, that a real prescriber reviewed your information, and that the medicine came through the licensed UK supply chain. If you're unsure whether Wegovy is the right option for you, or whether you'd be better suited to a different licensed treatment, our prescribers can discuss that as part of a free consultation. Check your eligibility and start your free consultation here.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.